Keep your critical coding and billing tools with you no matter where you work.
Create your Find-A-Code account today!
tci Part B Insider - 2005 Issue 6
Infusion: Check With Your Carrier About Tysabri Coding
Some advise J3590 for new miracle MS drugThe Food and Drug Administration approved a revolutionary new drug for multiple sclerosis, Tysabri, back in November. But providers are still coming to grips with coding for this medication. Physicians will administer Tysabri, also known by the generic name natalizumab, to treat and reduce the frequency of clinical relapses in relapsing forms of MS. The patient receives the drug intravenously every four weeks in either the inpatient or outpatient setting."There's no consistent coding or payment strategy for Tysabri yet," notes Neil Busis, chief of the division of neurology and director...
To read the full article, sign in and subscribe to tci Part B Insider.
Keep pace with evolving Medicare regulations with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI’s Part B Insider will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, the fee schedule, OIG target areas, and more.
Current newsletters added each month
Fully searchable archives - over 4800 articles
ALL years/issues back to 2003 organized by year and issue
Codes mentioned in articles are linked to Code Information pages
Code Information pages link back to related articles
This feature is currently unavailable for online purchase. For more information, please call 801-770-4203 or Contact Us.